Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCranswick Regulatory News (CWK)

Share Price Information for Cranswick (CWK)

Share Price is delayed by 15 minutes
Get Live Data
5,690.00    40.00 (0.71%)
Bid:
5,690.00
Ask:
5,700.00
Spread: 10.00 (0.176%)
Market Cap: £3.05b
CWK Live PriceLast checked at - London Stock Exchange

Intraday Cranswick Share Chart

First quarter trading statement

28 Jul 2025 07:00

RNS Number : 6977S
Cranswick PLC
28 July 2025
 

28th July 2025

 

Cranswick plc

("Cranswick" or "the Company" or "the Group")

 

 

First quarter trading statement

 

Cranswick, a leading UK food producer, today provides an update on trading for the 13 weeks to 28 June 2025.

 

Current trading

Trading in the first quarter of the new financial year has been strong, with revenue ahead across all product categories year-on-year. Group reported revenue was 9.7 per cent ahead of the same period last year, with Blakemans, which was acquired on 16 May 2025, making a positive contribution in line with expectations. Like-for-like1 revenue was up 7.9 per cent, driven by strong volume growth reflecting new business wins, closer alignment with key strategic retail partners and continued outperformance of premium added-value ranges with consumers' increasing appetite for natural protein as part of a healthy balanced diet.

 

Export revenue was strong, reflecting both volume growth and higher pricing following the reinstatement of the Norfolk fresh pork site's China export license in December 2024.  Poultry revenue grew strongly driven by the onboarding of new premium retail business at the Cooked and Prepared Poultry sites together with strong demand from the Eye fresh poultry site's anchor retail customer. Pet Products revenue was well ahead reflecting the successful ongoing roll out of the Pets at Home business.

 

We have further strengthened our relationship with Pets at Home with new premium own-label business now secured, supply is due to begin later in the year.

 

Investment

We are accelerating the pace of capital expenditure to add capacity, expand capability, and drive operating efficiencies across our 23 production facilities and extensive pig and poultry farming operations. During the period we made good progress on each of our major earnings enhancing capital projects. With new business secured, we have committed a further £14 million of investment at the Lincoln Pet Products site, to increase capacity and broaden the product range.

 

Financial position

As expected, net debt at the quarter end was higher than the March 2025 year end position reflecting cash spent on the Blakemans' acquisition, significant capital investment and seasonal working capital expansion, partially offset by strong free cash generation.

 

During the period the Group refinanced its banking facility on more favourable terms. The new agreement, which comprises a revolving credit facility of £360 million, is unsecured, and runs to July 2029 with the option to extend by a further two years. A further £90 million can be accessed on the same terms at any point during the term of the agreement. The new facility replaces the old £250 million revolving credit facility and provides comfortable headroom to support future growth and investment.

 

Outlook

We have made a strong start to the year, delivering volume-led revenue growth supported by a positive contribution from the newly acquired Blakemans business. Investment continues at pace across our farming operations and primary and added value processing facilities in line with our recently updated medium-term guidance. Looking ahead, the outlook for the current financial year ending 28 March 2026 remains in line with current market expectations2.

 

The Board remains confident that continued focus on the strengths of the Company, which include its long-standing customer relationships, breadth and quality of products, robust financial position and industry leading asset base, will support the further successful development of the Group during the current year and over the longer term.

 

Adam Couch, CEO of Cranswick, commented:

"We have made a strong start to the year, delivering volume-led revenue growth across all product categories. We continue to invest at pace across our asset base to drive strong returns.

 

"In line with the commitments we made on 20 May 2025, we have further strengthened our animal welfare compliance practices and checks. The independent expert veterinarian led review of these policies and procedures is well advanced, and we look forward to receiving its recommendations. We will provide a further update on this review in due course.

 

"Integration of the Blakemans business is progressing well and we have committed to further substantial investment in the Lincoln Pet Products site.

 

"Our continued positive progress reflects the substantial ongoing investment in our asset base and the quality and capability of our colleagues across the business."

 

Interim results

The Company's next scheduled comment on trading will be the interim results announcement for the 26 weeks ending 27 September 2025, on Tuesday 25 November 2025.

 

Enquiries:

 

Cranswick plc

01482 275 000

Mark Bottomley, Chief Financial Officer

Sodali & Co

+44 207 100 6451

Ben Foster / Louisa Henry / Molly Callaghan

cranswick@sodali.com

 

Notes:

1. Like-for-like revenue references excludes the current year contribution from current and prior year acquisitions prior to the anniversary of their purchase.

2. Market expectations for adjusted profit before tax as at 25th July 2025 range between £206.5m and £213.6m. The range reflects all published updated Broker analysis following release of our year end results on 20 May 2025.

3. Cranswick is a leading and innovative supplier of premium, fresh and added-value food products. The business employs over 15,400 people and operates from 23 well-invested, highly efficient facilities in the UK. Cranswick was formed in the early 1970s by farmers in East Yorkshire to produce animal feed and has since evolved into a business which produces a range of high-quality, predominantly fresh food, including fresh pork, poultry, convenience, gourmet products and pet food. The business develops innovative, great tasting food products to the highest standards of food safety and traceability. The Group supplies the major grocery multiples as well as the growing premium and discounter retail channels. Cranswick also has a strong presence in the 'food-to-go' sector and a substantial export business. Results for the 52 weeks to 29 March 2025 showed revenue of £2,723.3m and profit before tax of £181.6m. For more information go to: www.cranswick.plc.uk

4. At Cranswick, it is second nature for us to protect and nurture our environment while supporting people and communities to thrive. Guided by our sustainability strategy, Second Nature, we have seamlessly integrated our sustainability commitments into the core of our business model, which in turn shapes our decision-making, culture, and actions. For more information on our Second Nature strategy, please visit: www.cranswick.plc.uk/sustainability

5. This announcement is based on information sourced from unaudited management accounts.

6. This announcement contains certain forward looking statements. By their nature, forward looking statements involve a number of risks, uncertainties or assumptions that could cause actual results or events to differ materially from those expressed or implied by those statements. Forward looking statements regarding past trends or activities should not be taken as representation that such trends or activities will continue in the future. Accordingly undue reliance should not be placed on forward looking statements.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFVLDAIRFIE
Date   Source Headline
3rd Jun 20263:37 pmRNSDirector/PDMR Shareholding
1st Jun 20268:41 amRNSTotal Voting Rights
26th May 202610:27 amRNSDirector/PDMR Shareholding
22nd May 20263:39 pmRNSDirector/PDMR Shareholding
21st May 20263:27 pmRNSDirectors Dealing
19th May 20267:00 amRNSPreliminary Results
13th May 202611:03 amRNSIssue of Equity/Admission to Trading
1st May 202611:53 amRNSTotal Voting Rights
22nd Apr 20266:05 pmRNSDirector/PDMR Shareholding
1st Apr 20263:44 pmRNSTotal Voting Rights
31st Mar 202612:33 pmRNSIssue of Equity/Admission to Trading
25th Mar 20267:00 amRNSDirector/PDMR Shareholding
24th Mar 202610:37 amRNSDirector/PDMR Shareholding
24th Mar 202610:37 amRNSDirector/PDMR Shareholding
23rd Mar 202610:31 amRNSDirector/PDMR Shareholding
12th Mar 202612:07 pmRNSHolding(s) in Company
10th Mar 20264:47 pmRNSHolding(s) in Company
4th Mar 20265:17 pmRNSHolding(s) in Company
2nd Mar 20263:24 pmRNSHolding(s) in Company
2nd Mar 20263:21 pmRNSTotal Voting Rights
2nd Mar 20263:21 pmRNSDirector/PDMR Shareholding
2nd Mar 20263:21 pmRNSDirector/PDMR Shareholding
2nd Mar 20263:18 pmRNSDirector/PDMR Shareholding
26th Feb 20263:55 pmRNSHolding(s) in Company
24th Feb 202611:31 amRNSDirector/PDMR Shareholding
18th Feb 20265:55 pmRNSHolding(s) in Company
18th Feb 202612:11 pmRNSHolding(s) in Company
2nd Feb 20263:54 pmRNSTotal Voting Rights
30th Jan 20266:10 pmRNSHolding(s) in Company
30th Jan 20267:00 amRNSHolding(s) in Company
28th Jan 20265:59 pmRNSHolding(s) in Company
27th Jan 20267:00 amRNSThird quarter trading statement
23rd Jan 202611:27 amRNSDirector/PDMR Shareholding
22nd Jan 20264:51 pmRNSHolding(s) in Company
22nd Jan 20263:17 pmRNSHolding(s) in Company
19th Jan 20267:00 amRNSHolding(s) in Company
5th Jan 202610:52 amRNSTotal Voting Rights
23rd Dec 202512:48 pmRNSDirector/PDMR Shareholding
23rd Dec 202512:48 pmRNSDirector/PDMR Shareholding
23rd Dec 20257:00 amRNSHolding(s) in Company
23rd Dec 20257:00 amRNSHolding(s) in Company
22nd Dec 202511:33 amRNSDirector/PDMR Shareholding
22nd Dec 202511:33 amRNSDirector/PDMR Shareholding
19th Dec 20253:18 pmRNSHolding(s) in Company
19th Dec 20253:18 pmRNSHolding(s) in Company
19th Dec 20257:00 amRNSHolding(s) in Company
19th Dec 20257:00 amRNSHolding(s) in Company
5th Dec 20259:15 amRNSHolding(s) in Company
1st Dec 202510:49 amRNSTotal Voting Rights
25th Nov 20257:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.